Payment overview · 2025
General Payments
$1,155.31
64 reported records · 20 companies
Healthcare provider profile · identity verified
James E. Wheeler, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LOUISVILLE, KY · NPI 1275537094
Verified facts
What the public records show
CMS Open Payments records show James E. Wheeler, M.D. received $1,155.31 in general payments during 2025 across 64 reported records.
Novo Nordisk Inc accounted for 14.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Fanapt, Jardiance, Ozempic, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY as an associated drug or biological on 46 records involving 42 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Abilify by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 264 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 264 claims for Eliquis by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $171.25 | 14.8% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $165.35 | 14.3% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $143.87 | 12.4% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $95.21 | 8.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $83.33 | 7.2% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.29 | 5.8% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $64.67 | 5.6% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.23 | 4.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.31 | 4.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.92 | 4.1% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $44.18 | 3.8% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.28 | 2.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.84 | 2.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.63 | 1.9% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $17.13 | 1.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.09 | 1.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.56 | 1.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.98 | 1.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.69 | 1.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.50 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,155.31 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $150.34 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $128.18 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $102.19 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $95.21 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $89.51 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $75.84 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $64.67 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $51.23 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $49.31 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.13 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $49.13 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $48.61 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.92 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.92 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $44.18 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $36.63 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $31.28 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $31.28 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $27.84 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 264 | exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 95 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
118 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
141 | 40 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 26 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ABILIFY open payments reported associated product |
CMS Open Payments — General Payments 46 supporting records · 42 recipient NPIs · example record 1184501721 |
Abilify · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
264 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
264 | 44 |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1342 | 300 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1245 | 232 |
| Amlodipine Besylate | Amlodipine Besylate | 1011 | 249 |
| Pantoprazole Sodium | Pantoprazole Sodium | 576 | 141 |
| Lisinopril | Lisinopril | 559 | 141 |
| Losartan Potassium | Losartan Potassium | 546 | 147 |
| Omeprazole | Omeprazole | 511 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 470 | 112 |
| Montelukast Sodium | Montelukast Sodium | 461 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 431 | 108 |
| Fluticasone Propionate | Fluticasone Propionate | 383 | 96 |
| Trazodone Hcl | Trazodone Hcl | 376 | 101 |
| Hydrochlorothiazide | Hydrochlorothiazide | 332 | 83 |
| Sertraline Hcl | Sertraline Hcl | 318 | 69 |
| Alprazolam | Alprazolam | 311 | 64 |
| Meloxicam | Meloxicam | 310 | 75 |
| Famotidine | Famotidine | 307 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 290 | 70 |
| Eliquis | Apixaban | 264 | 44 |
| Furosemide | Furosemide | 259 | 57 |
| Potassium Chloride | Potassium Chloride | 247 | 64 |
| Baclofen | Baclofen | 244 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 239 | 59 |
| Gabapentin | Gabapentin | 228 | 64 |
| Tramadol Hcl | Tramadol Hcl | 221 | 54 |
| Simvastatin | Simvastatin | 219 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 207 | 50 |
| Ezetimibe | Ezetimibe | 205 | 51 |
| Metformin Hcl Er | Metformin Hcl | 205 | 50 |
| Allopurinol | Allopurinol | 197 | 58 |
| Irbesartan | Irbesartan | 189 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 181 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 177 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 177 | 31 |
| Celecoxib | Celecoxib | 174 | 49 |
| Glipizide Er | Glipizide | 174 | 45 |
| Levetiracetam | Levetiracetam | 166 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 165 | 38 |
| Aripiprazole | Aripiprazole | 159 | 22 |
| Risperidone | Risperidone | 159 | 14 |
| Metformin Hcl | Metformin Hcl | 157 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 33 |
| Lamotrigine | Lamotrigine | 144 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 143 | 37 |
| Synthroid | Levothyroxine Sodium | 141 | 40 |
| Carvedilol | Carvedilol | 137 | 34 |
| Clonazepam | Clonazepam | 131 | 22 |
| Alendronate Sodium | Alendronate Sodium | 129 | 28 |
| Konvomep | Omeprazole/Sodium Bicarbonate | 128 | suppressed |
| Methylprednisolone | Methylprednisolone | 122 | 108 |
| Diclofenac Sodium | Diclofenac Sodium | 121 | 47 |
| Paroxetine Hcl | Paroxetine Hcl | 120 | 22 |
| Linzess | Linaclotide | 118 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 117 | 12 |
| Olanzapine | Olanzapine | 114 | 11 |
| Azithromycin | Azithromycin | 113 | 106 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 113 | 20 |
| Lansoprazole | Lansoprazole | 109 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 105 | 82 |
| Mirtazapine | Mirtazapine | 105 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 104 | 27 |
| Buspirone Hcl | Buspirone Hcl | 100 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 95 | 20 |
| Jardiance | Empagliflozin | 95 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 93 | 14 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 90 | suppressed |
| Sucralfate | Sucralfate | 90 | 22 |
| Ozempic | Semaglutide | 89 | 14 |
| Eszopiclone | Eszopiclone | 86 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 86 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 46 |
| Dicyclomine Hcl | Dicyclomine Hcl | 85 | 20 |
| Valsartan | Valsartan | 85 | 21 |
| Fenofibrate | Fenofibrate | 84 | 18 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 84 | 13 |
| Topiramate | Topiramate | 82 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 81 | 62 |
| Prednisone | Prednisone | 81 | 38 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 80 | 24 |
| Atenolol | Atenolol | 77 | 18 |
| Bupropion Xl | Bupropion Hcl | 76 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 38 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 76 | 16 |
| Finasteride | Finasteride | 74 | 14 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 74 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 71 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 71 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 70 | 15 |
| Glimepiride | Glimepiride | 70 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 68 | 25 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 66 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | 16 |
| Aptiom | Eslicarbazepine Acetate | 62 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 61 | suppressed |
| Lorazepam | Lorazepam | 61 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 61 | 38 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 60 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 15 |
| Valacyclovir | Valacyclovir Hcl | 59 | 26 |
| Carbamazepine | Carbamazepine | 58 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 58 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 55 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 55 | 20 |
| Dantrolene Sodium | Dantrolene Sodium | 54 | suppressed |
| Diazepam | Diazepam | 54 | 18 |
| Memantine Hcl | Memantine Hcl | 54 | suppressed |
| Vascepa | Icosapent Ethyl | 53 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 52 | 14 |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Acyclovir | Acyclovir | 51 | 15 |
| Divalproex Sodium Er | Divalproex Sodium | 51 | suppressed |
| Enulose | Lactulose | 51 | suppressed |
| Paliperidone Er | Paliperidone | 50 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 49 | suppressed |
| Ramipril | Ramipril | 49 | 13 |
| Lactulose | Lactulose | 47 | suppressed |
| Ibuprofen | Ibuprofen | 46 | 21 |
| Lovastatin | Lovastatin | 46 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 14 |
| Liothyronine Sodium | Liothyronine Sodium | 45 | 12 |
| Nystatin | Nystatin | 45 | 18 |
| Terazosin Hcl | Terazosin Hcl | 45 | suppressed |
| Pregabalin | Pregabalin | 44 | 15 |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Amoxicillin | Amoxicillin | 43 | 25 |
| Cephalexin | Cephalexin | 43 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | 15 |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 42 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 30 |
| Raloxifene Hcl | Raloxifene Hcl | 41 | suppressed |
| Fluconazole | Fluconazole | 40 | 26 |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | 11 |
| Mupirocin | Mupirocin | 37 | 12 |
| Oxcarbazepine | Oxcarbazepine | 37 | suppressed |
| Metronidazole | Metronidazole | 36 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Rexulti | Brexpiprazole | 36 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 35 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Lubiprostone | Lubiprostone | 35 | suppressed |
| Zonisamide | Zonisamide | 35 | suppressed |
| Cefdinir | Cefdinir | 34 | 30 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 32 | suppressed |
| Cabergoline | Cabergoline | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 22 |
| Motegrity | Prucalopride Succinate | 31 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 30 | suppressed |
| Ketoconazole | Ketoconazole | 30 | 13 |
| Sodium Fluoride | Fluoride (Sodium) | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 27 | suppressed |
| Budesonide | Budesonide | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Scopolamine | Scopolamine | 27 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 26 | suppressed |
| Topiramate Er | Topiramate | 26 | suppressed |
| Carbamazepine Er | Carbamazepine | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 24 | 15 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Niacin Er | Niacin | 23 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 13 |
| Trimethoprim | Trimethoprim | 21 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Levocarnitine | Levocarnitine | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Prolia | Denosumab | 18 | suppressed |
| Abilify | Aripiprazole | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Junel | Norethindrone Ac/Eth Estradiol | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 17 |
| Trulicity | Dulaglutide | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Epinephrine | Epinephrine | 16 | 16 |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Sulfacetamide Sodium | Sulfacetamide Sodium | 15 | suppressed |
| Tacrolimus | Tacrolimus | 15 | suppressed |
| Alprazolam Er | Alprazolam | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Nortrel | Norethindrone-Ethin. Estradiol | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Admelog | Insulin Lispro | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Cryselle | Norgestrel-Ethinyl Estradiol | 13 | suppressed |
| Epinastine Hcl | Epinastine Hcl | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Olanzapine Odt | Olanzapine | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Fanapt | Iloperidone | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bacitracin-Polymyxin | Bacitracin/Polymyxin B Sulfate | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Humira(Cf) Pen | Adalimumab | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,155.31 · 64 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Auvelity, CAPLYTA, COMIRNATY, ELIQUIS, FANAPT, HETLIOZ, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OFEV, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND, ZORYVE, ZURZUVAE | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error